Search research articles
Contact Us
Filters
Showing results (11-20 of 27) with videos related to
Page
of 3
Sort By:
Expert Opinion on Drug Discovery
|
May 27, 2014
Discovery and preclinical development of vismodegib
Stephen E Gould, Jennifer A Low, James C Marsters, et al.
Investigational New Drugs
|
August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
Neelima Denduluri, James J Lee, Janice Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
Neelima Denduluri, Jennifer A Low, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2011
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors
Patricia M Lorusso, Antonio Jimeno, Grace Dy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding
Richard A Graham, Bert L Lum, Sravanthi Cheeti, et al.
British Journal of Clinical Pharmacology
|
March 31, 2012
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
Richard A Graham, Cornelis E C A Hop, Marie T Borin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
Jennifer A Low, Suparna B Wedam, James J Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 24, 2011
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
Richard A Graham, Bert L Lum, Glenn Morrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2012
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer
Jordan Berlin, Johanna C Bendell, Lowell L Hart, et al.
The New England Journal of Medicine
|
September 4, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
Charles M Rudin, Christine L Hann, John Laterra, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 27) with videos related to
Sort By:
Page
of 3
Expert Opinion on Drug Discovery
|
May 27, 2014
Discovery and preclinical development of vismodegib
Stephen E Gould, Jennifer A Low, James C Marsters, et al.
Investigational New Drugs
|
August 26, 2006
Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
Neelima Denduluri, James J Lee, Janice Walshe, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 4, 2007
Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes
Neelima Denduluri, Jennifer A Low, James J Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 15, 2011
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors
Patricia M Lorusso, Antonio Jimeno, Grace Dy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 9, 2011
Pharmacokinetics of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors: the role of alpha-1-acid glycoprotein binding
Richard A Graham, Bert L Lum, Sravanthi Cheeti, et al.
British Journal of Clinical Pharmacology
|
March 31, 2012
Single and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjects
Richard A Graham, Cornelis E C A Hop, Marie T Borin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer
Jennifer A Low, Suparna B Wedam, James J Lee, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 24, 2011
A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
Richard A Graham, Bert L Lum, Glenn Morrison, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 20, 2012
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer
Jordan Berlin, Johanna C Bendell, Lowell L Hart, et al.
The New England Journal of Medicine
|
September 4, 2009
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449
Charles M Rudin, Christine L Hann, John Laterra, et al.
Page
of 3